17:25–17:50

Abstract LBA1

Randomized comparison of adjuvant   treatment with aromatase inhibitor (AI) exemestane (E) plus ovarian function   suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with   hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of   IBCSG TEXT and SOFT trials.

比较依西美坦联合卵巢去势和他莫昔芬联合卵巢去势在绝经前激素受体阳性早期乳腺癌患者的辅助治疗研究：IBCSG TEXT试验和SOFT试验联合分析。

廖  宁(Ning Liao)

Abstract 500

Bevacizumab (Bv) in the adjuvant treatment   of HER2-negative breast cancer: Final results from Eastern Cooperative   Oncology Group E5103.

贝伐单抗在HER2阴性乳腺癌的辅助治疗研究：东部肿瘤协作组织E5103研究最终结果。

Abstract 504

Prognostic associations of 25OH vitamin D   in NCIC CTG MA.21, a phase III adjuvant RCT of three   chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC).

在高风险乳腺癌患者人群使用三种辅助化疗方案EC/T、CEF、AC/T的III期临床试验中（NCIC CTG MA.21），关于预后和25羟基-维生素D水平关系的临床研究。

17:50–18:05

专家评述

Discussion Topic: Optimal   adjuvant therapy for early resectable HER2 –ive breast cancer

讨论主题：早期可手术的HER2阴性乳腺癌患者的最佳辅助治疗方案

Peter   Yu

翻译：

张  剑(Jian Zhang)

18:05–18:10

讨论(Q &   A)

于  丁(Ding Yu)

胡夕春(Xi-Chun Hu)

Peter Yu